What Happened?
, -based Avalyn Pharma Appointed Douglas Carlson as Chief Financial Officer
About the Company
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
About the Person
Douglas Carlson is Chief Financial Officer at Avalyn Pharma. Previously, Douglas held various senior HR leadership roles in the industry.
Info Source
News
Short Profile